Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 350 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Temodar Clear all
Active, not recruiting Phase 1 Interventional

Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma

NCT03011671
View directory record Official record
Conditions
Malignant Glioma of Brain
Interventions
Acetazolamide, Temozolomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain

NCT00012116
View directory record Official record
Conditions
Metastatic Cancer
Interventions
temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 1 Interventional

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

NCT00629187
View directory record Official record
Conditions
Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions
Temozolomide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

NCT00792012
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Hypofractionated Intensity-Modulated Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT03425292
View directory record Official record
Conditions
Newly Diagnosed High Grade Glioma
Interventions
Temozolomide, conformal brain radiation therapy, Nivolumab, Ipilimumab, Bevacizumab, 5-day Temozolomide, Lomustine, Nivolumab monotherapy
Drug · Radiation
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT02715609
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Disulfiram, Copper Gluconate, Surgery, Radiation, Temozolomide
Drug · Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

NCT01051596
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Temozolomide, ABT-888
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

NCT00826241
View directory record Official record
Conditions
Brain Tumors, Spinal Cord Tumors
Interventions
Temozolomide, Lapatinib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
6
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

NCT00669669
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor, Proton Beam Radiation Therapy, Temozolomide
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma

NCT00525525
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab, Tarceva, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 25, 2026, 3:30 PM EDT
Recruiting Phase 1 Interventional

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

NCT05698524
View directory record Official record
Conditions
Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
Interventions
PCI 24781, Temozolomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MLN8237 in Combination With Irinotecan and Temozolomide

NCT01601535
View directory record Official record
Conditions
Neuroblastoma
Interventions
MLN8237, Irinotecan, Temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
12 Months to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional Results available

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

NCT03363659
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Disulfiram, Copper gluconate, Temozolomide
Drug · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

NCT01977677
View directory record Official record
Conditions
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Interventions
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study
Radiation · Drug · Other
Lead sponsor
Lawrence Recht
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 25, 2026, 3:30 PM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Oct 25, 2026, 3:30 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional Results available

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

NCT02113007
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma
Interventions
Rituximab plus Temozolomide
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New Haven, Connecticut • Hollywood, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275
View directory record Official record
Conditions
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Interventions
Chemotherapy with Temodar., Radiation therapy
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases

NCT00582075
View directory record Official record
Conditions
Cancer, Brain Metastases
Interventions
temozolomide
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Active, not recruiting Phase 1 Interventional

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT04047706
View directory record Official record
Conditions
Glioblastoma
Interventions
IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide, IDO1 Inhibitor BMS-986205 50 mg, IDO1 Inhibitor BMS-986205 100 mg
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475
View directory record Official record
Conditions
Recurrent Malignant Glioma, Brain Glioblastoma
Interventions
OKN-007, Temozolomide (TMZ)
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 25, 2026, 3:30 PM EDT